Repligen (RGEN)
(Delayed Data from NSDQ)
$165.66 USD
-2.20 (-1.31%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $165.78 +0.12 (0.07%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Repligen (RGEN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$205.64 | $230.00 | $175.00 | 22.51% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Repligen comes to $205.64. The forecasts range from a low of $175.00 to a high of $230.00. The average price target represents an increase of 22.51% from the last closing price of $167.86.
Analyst Price Targets (11)
Broker Rating
Repligen currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.58 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.58 | 1.58 | 1.58 | 1.58 | 1.58 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
3/1/2024 | The Benchmark Company | Robert Wasserman | Hold | Hold |
2/15/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
11/6/2023 | William Blair | Matt Larew | Strong Buy | Strong Buy |
8/3/2023 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
8/3/2023 | Craig-Hallum | Matthew G Hewitt | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.58 |
ABR (Last week) | 1.58 |
# of Recs in ABR | 12 |
Average Target Price | $205.64 |
LT Growth Rate | 21.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | 0.29 |